Captaru
  • Grants
  • Volunteers
  • Community
  • Pricing
  • About
    Who We AreOur PartnersJobs
  • Transparency
  • Blog
  • Contact
Captaru Logo

Starting from what we can do and think, our strength is bringing our own and third-party social projects to life.

proyectos@captaru.org
CAPTARU
  • ABOUT US
  • PROJECTS
  • Grant management
  • NGO platform
  • EU funding
  • TRANSPARENCY
  • CONTACT
FOLLOW US
  • Facebook
  • Twitter
  • LinkedIn
  • Youtube
Preferred source on Google
JOIN OUR NEWSLETTER AND NEVER MISS AN OPPORTUNITY
Legal NoticeDisclaimerCookie PolicyPrivacy StatementSubscription Terms

Fundación Plaza de Castilla, CIF G84070945, registered at Serrano Anguita 13, 28004 Madrid.

CAPTARU IS A PROJECT DEVELOPED WITH PASSION BY FUNDACIÓN PLAZA DE CASTILLA © 2026 ALL RIGHTS RESERVED

Back to list
Start a proposal with Captaru
🇺🇸GRANTS_GOVOPENGRANT18 days left

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

🏛 GRANTS_GOV · 📍 US

Total budget

$250,000

OPENING

Oct 15, 2024

CLOSING

Oct 14, 2026

Category

Education / Health

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

Official source

View official source ↗

Eligible beneficiaries

  • Public housing authorities/Indian housing authorities
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Small businesses
  • State governments
  • Native American tribal governments (Federally recognized)
  • County governments
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Public and State controlled institutions of higher education
  • For profit organizations other than small businesses
  • Private institutions of higher education
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • City or township governments
  • Independent school districts
  • Special district governments
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Related calls

  • National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)
  • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
  • Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
  • NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
  • Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
See all open grants